Vertex Pharmaceuticals Crecimiento futuro
Future controles de criterios 5/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Vertex Pharmaceuticals de 47.3% y 9% por año respectivamente. Se prevé que el BPA crezca en un 47.4% al año. Se espera que la rentabilidad financiera sea de 22.2% en 3 años.
Información clave
47.3%
Tasa de crecimiento de los beneficios
47.4%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 27.5% |
| Tasa de crecimiento de los ingresos | 9.0% |
| Rentabilidad financiera futura | 22.2% |
| Cobertura de analistas | Good |
| Última actualización | 06 Nov 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 08
Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Recent updates
Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
Nov 05Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Oct 18Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)
Oct 10Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug
Sep 15Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Sep 05Vertex Stock: Came For CF Drugs, Staying For Gene Therapy
Aug 02Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?
Jul 11Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
Jul 09If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jun 20Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales
Jun 17Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
Jun 04Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet
May 09Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 08Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely
Apr 05Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?
Mar 15Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings
Feb 22Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Jan 15Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Dec 25An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued
Nov 13With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Oct 02Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jul 31We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease
Jul 03Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 12,902 | 4,905 | 5,460 | N/A | 24 |
| 12/31/2025 | 11,775 | 4,277 | 4,756 | N/A | 33 |
| 12/31/2024 | 10,880 | -422 | 581 | N/A | 30 |
| 9/30/2024 | 10,626 | -480 | N/A | N/A | N/A |
| 6/30/2024 | 10,337 | -490 | -1,426 | -944 | N/A |
| 3/31/2024 | 10,185 | 4,019 | 3,479 | 3,944 | N/A |
| 12/31/2023 | 9,869 | 3,620 | 3,279 | 3,537 | N/A |
| 9/30/2023 | 9,654 | 3,470 | 4,205 | 4,381 | N/A |
| 6/30/2023 | 9,505 | 3,365 | 3,879 | 4,068 | N/A |
| 3/31/2023 | 9,208 | 3,260 | 3,890 | 4,074 | N/A |
| 12/31/2022 | 8,931 | 3,322 | 3,925 | 4,130 | N/A |
| 9/30/2022 | 8,701 | 3,273 | 3,814 | 4,047 | N/A |
| 6/30/2022 | 8,350 | 3,195 | 3,787 | 4,018 | N/A |
| 3/31/2022 | 7,948 | 2,451 | 2,451 | 2,679 | N/A |
| 12/31/2021 | 7,574 | 2,342 | 2,409 | 2,644 | N/A |
| 9/30/2021 | 7,130 | 2,176 | 1,919 | 2,140 | N/A |
| 6/30/2021 | 6,684 | 1,992 | 1,777 | 2,121 | N/A |
| 3/31/2021 | 6,415 | 2,762 | 3,048 | 3,359 | N/A |
| 12/31/2020 | 6,206 | 2,712 | 2,994 | 3,254 | N/A |
| 9/30/2020 | 5,991 | 2,691 | 2,979 | 3,208 | N/A |
| 6/30/2020 | 5,403 | 2,081 | 2,557 | 2,635 | N/A |
| 3/31/2020 | 4,819 | 1,511 | 1,983 | 2,060 | N/A |
| 12/31/2019 | 4,163 | 1,177 | 1,494 | 1,569 | N/A |
| 9/30/2019 | 3,620 | 2,144 | 1,363 | 1,438 | N/A |
| 6/30/2019 | 3,454 | 2,215 | 1,413 | 1,484 | N/A |
| 3/31/2019 | 3,265 | 2,155 | 1,258 | 1,342 | N/A |
| 12/31/2018 | 3,048 | 2,096 | 1,175 | 1,270 | N/A |
| 9/30/2018 | 2,829 | 647 | 1,060 | 1,183 | N/A |
| 6/30/2018 | 2,623 | 415 | N/A | 972 | N/A |
| 3/31/2018 | 2,415 | 226 | N/A | 832 | N/A |
| 12/31/2017 | 2,489 | 263 | N/A | 845 | N/A |
| 9/30/2017 | 2,296 | 196 | N/A | 762 | N/A |
| 6/30/2017 | 2,131 | 259 | N/A | 658 | N/A |
| 3/31/2017 | 2,019 | 177 | N/A | 517 | N/A |
| 12/31/2016 | 1,702 | -112 | N/A | 236 | N/A |
| 9/30/2016 | 1,661 | -219 | N/A | 121 | N/A |
| 6/30/2016 | 1,557 | -275 | N/A | -7 | N/A |
| 3/31/2016 | 1,292 | -399 | N/A | -158 | N/A |
| 12/31/2015 | 1,032 | -556 | N/A | -365 | N/A |
| 9/30/2015 | 759 | -659 | N/A | -576 | N/A |
| 6/30/2015 | 628 | -734 | N/A | -602 | N/A |
| 3/31/2015 | 600 | -704 | N/A | -620 | N/A |
| 12/31/2014 | 580 | -738 | N/A | -573 | N/A |
| 9/30/2014 | 787 | -582 | N/A | -362 | N/A |
| 6/30/2014 | 830 | -530 | N/A | -289 | N/A |
| 3/31/2014 | 1,002 | -428 | N/A | -162 | N/A |
| 12/31/2013 | 1,212 | -504 | N/A | -61 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que VRTX sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).
Beneficios vs. Mercado: Se prevé que VRTX sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que VRTX sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (9% al año) de VRTX crezcan más rápidamente que los del mercado US (8.8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 9% al año) de VRTX crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de VRTX sea alta dentro de 3 años (22.2%)